Monte Rosa Therapeutics (GLUE) Net Cash Flow Growth (1y) (2021 - 2026)
Powered by 
Analysis
Monte Rosa Therapeutics (GLUE) Net Cash Flow Growth (1y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 172.72% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 53.21% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 47.11% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 75.60% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -100.75% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 149.49% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -104.22% |
| 10 | Monte Rosa Therapeutics | 1.40 Bn | 771.57 Mn | - | -672.48% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -672.48% |
| Mar 31, 2026 | 120.57% |
| Dec 31, 2025 | -179.54% |
| Sep 30, 2025 | 728.35% |
| Jun 30, 2025 | -199.26% |
| Mar 31, 2025 | -419.16% |
| Dec 31, 2024 | 42.73% |
| Sep 30, 2024 | 39.48% |
| Jun 30, 2024 | 263.22% |
| Mar 31, 2024 | -816.59% |
| Dec 31, 2023 | 220.25% |
| Sep 30, 2023 | 38.64% |
| Jun 30, 2023 | 83.92% |
| Mar 31, 2023 | 98.53% |
| Dec 31, 2022 | -231.14% |
| Sep 30, 2022 | -13.05% |
| Jun 30, 2022 | -118.32% |
| Mar 31, 2022 | -263.94% |
| Dec 31, 2021 | -77.63% |
| Sep 30, 2021 | -75.02% |